Back
About the Global Fund
People & Structures
Back
Funding Model
Investments & Results
-
Explore contributions, investments and results in our fight against AIDS, tuberculosis and malaria around the world.
- Data Explorer
- Funding Decisions
- Data Service
Back
News
-
14 July 2021
Global Fund Applauds Switzerland’s Leadership in The Global Fight Against COVID-19 -
24 June 2021
Gavi And The Global Fund Sign Groundbreaking Agreement With International Federation Of Accountants To Support In-Country Financial Management -
21 May 2021
G20 Reaffirms Commitment to ACT-A to Fight COVID-19
Updates
-
16 July 2021
COVID-19 Response Mechanism Guidelines: Recent Updates -
15 July 2021
Grant Entity Data Trainings for Country Coordinating Mechanisms, Principal Recipients and Local Fund Agents -
14 July 2021
Global Fund Applauds Switzerland’s Leadership in The Global Fight Against COVID-19 -
08 July 2021
Considering Liquid Oxygen in C19RM Funding Requests -
01 July 2021
New C19RM Submission Window: 17 September 2021
Stories
-
21 July 2021
In Eswatini, young women are leading the fight against HIV and COVID-19 -
21 July 2021
Every country’s COVID-19 response is underpinned by resilient and sustainable systems for health -
08 July 2021
One year into the COVID-19 pandemic, testing is as vital as ever -
07 July 2021
“You’re part of something bigger”: delivering lifesaving COVID-19 diagnostic tests in South Africa
Back
Featured Publication
Documents by type
Opportunity for Evaluation of Selected Medicines
20 November 2020
The Global Fund, Stop TB Partnership Global Drug Facility and Unitaid are inviting manufacturers of antiretroviral (HIV/AIDS), antihepatitis B and C, antituberculosis and antimalarial medicines to submit an expression of interest to have their products evaluated by the Expert Review Panel for Pharmaceutical Products.
Detailed information about the review process and submission requirements for this Round 23 opportunity can be found in the document below.
Once all expressions of interest have been received, the Expert Review Panel will be responsible for reviewing and judging their eligibility and whether to perform a risk-benefit assessment of the products submitted.
The deadline for submission of an expression of interest is Friday 08 January 2021 (COB). At the end of January 2021, the Global Fund Secretariat will communicate to manufacturers the outcomes of the review of the completeness of documents submitted. The results of the product evaluations are expected for release by the end of March 2021.
- Invitation to Antiretroviral (HIV/AIDS), Antihepatitis B and C, Antituberculosis and Antimalarial Medicines Manufacturers to Submit an Expression of Interest for Product Evaluation by the Global Fund Expert Review Panel for Pharmaceutical ProductsInvitation to Antiretroviral (HIV/AIDS), Antihepatitis B and C, Antituberculosis and Antimalarial Medicines Manufacturers to Submit an Expression of Interest for Product Evaluation by the Global Fund Expert Review Panel for Pharmaceutical Products
download in English
The Global Fund uses cookies for anonymized statistics on website use and content performance to help us improve and adapt the website. To consent to the use of cookies, please click “Accept”. To learn more about your rights and options, please read our Privacy Statement.